281 related articles for article (PubMed ID: 33080602)
1. Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review.
Muñoz-Jiménez M; Zaarkti A; García-Arnés JA; García-Casares N
Dement Geriatr Cogn Disord; 2020; 49(5):423-434. PubMed ID: 33080602
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
Cao B; Rosenblat JD; Brietzke E; Park C; Lee Y; Musial N; Pan Z; Mansur RB; McIntyre RS
Diabetes Obes Metab; 2018 Oct; 20(10):2467-2471. PubMed ID: 29790638
[TBL] [Abstract][Full Text] [Related]
3. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S
J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101
[TBL] [Abstract][Full Text] [Related]
4. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
[TBL] [Abstract][Full Text] [Related]
5. [The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].
Ishmuratova AN; Abramov MA; Kuznetsov KO; Ivanyuta MV; Shakirova ZF; Kitapova AI; Usmonov MD; Chernousova LM; Valeeva LI; Kuznetsova AY; Baislamov AS; Shaihetdinova AR; Mirgaliev AA; Orozberdiev ST; Yakupova KI
Probl Endokrinol (Mosk); 2023 Nov; 69(5):73-83. PubMed ID: 37968954
[TBL] [Abstract][Full Text] [Related]
6. Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.
Avgerinos KI; Kalaitzidis G; Malli A; Kalaitzoglou D; Myserlis PG; Lioutas VA
J Neurol; 2018 Jul; 265(7):1497-1510. PubMed ID: 29392460
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Alagiakrishnan K; Sankaralingam S; Ghosh M; Mereu L; Senior P
Discov Med; 2013 Dec; 16(90):277-86. PubMed ID: 24333407
[TBL] [Abstract][Full Text] [Related]
8. Antidiabetic Drugs in the Treatment of Alzheimer's Disease.
Michailidis M; Tata DA; Moraitou D; Kavvadas D; Karachrysafi S; Papamitsou T; Vareltzis P; Papaliagkas V
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563031
[TBL] [Abstract][Full Text] [Related]
9. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
10. New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.
Zhong KL; Chen F; Hong H; Ke X; Lv YG; Tang SS; Zhu YB
Metab Brain Dis; 2018 Aug; 33(4):1009-1018. PubMed ID: 29626315
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone for the treatment of Alzheimer's disease.
Galimberti D; Scarpini E
Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860
[TBL] [Abstract][Full Text] [Related]
12. Diabetes drugs in the fight against Alzheimer's disease.
Boccardi V; Murasecco I; Mecocci P
Ageing Res Rev; 2019 Sep; 54():100936. PubMed ID: 31330313
[TBL] [Abstract][Full Text] [Related]
13. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MG; Tabet N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
[TBL] [Abstract][Full Text] [Related]
14. Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents.
Jankowska A; Wesołowska A; Pawłowski M; Chłoń-Rzepa G
Curr Med Chem; 2020; 27(39):6658-6681. PubMed ID: 31604406
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Cardoso S; Moreira PI
Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
[TBL] [Abstract][Full Text] [Related]
16. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.
Jojo GM; Kuppusamy G
J Clin Pharm Ther; 2019 Jun; 44(3):337-348. PubMed ID: 30738020
[TBL] [Abstract][Full Text] [Related]
17. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.
Rosenbloom MH; Barclay TR; Pyle M; Owens BL; Cagan AB; Anderson CP; Frey WH; Hanson LR
CNS Drugs; 2014 Dec; 28(12):1185-9. PubMed ID: 25373630
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis.
Liu J; Wang LN
Expert Rev Neurother; 2019 Jun; 19(6):475-480. PubMed ID: 31092051
[No Abstract] [Full Text] [Related]
19. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
